☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
NMIBC
The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC
August 16, 2021
Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NM...
December 2, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
